Sinovac Biotech, Net Tangible Assets

Sinovac Biotech,'s net tangible assets stands at $12B as of June 2024. That compares with $12B in the prior-year period — down 6.0% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Sinovac Biotech, reported $12B in net tangible assets versus $12B a year earlier — a 6.0% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $12B in the prior-year period — down 6.0% year over year. Sustained growth in net tangible assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Sinovac Biotech,'s net tangible assets evolved across reporting periods, while the comparison chart places SVA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, net tangible assets is commonly used to spot outliers. Sinovac Biotech,'s reading of $12B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.